Compositions comprising sulforaphane or a sulforaphane precursor and magnesium

Abstract

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations.

What is claimed: 
     
         1 . An orally administrable composition comprising:
 a sulforaphane precursor;   a glucosidase enzyme capable of converting the sulforaphane precursor to sulforaphane;   a cofactor of the enzyme; and   magnesium or a salt or complex thereof;   the orally administrable composition providing a magnesium:sulforaphane precursor ratio of from about 1:1 to about 25:1.   
     
     
         2 . The orally administrable composition of  claim 1 , wherein the sulforaphane precursor comprises glucoraphanin. 
     
     
         3 . The orally administrable composition of  claim 1 , wherein the enzyme capable of converting the sulforaphane precursor to sulforaphane comprises myrosinase. 
     
     
         4 . The orally administrable composition of  claim 1 , wherein the enzyme cofactor comprises ascorbic acid. 
     
     
         5 . The orally administrable composition of  claim 1 , wherein the composition further comprises one or more additional components selected from the group consisting of:
 vitamin K2, quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiables unsaponifiable, a vitamin, coffee fruit, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols.   
     
     
         6 . The orally administrable composition of  claim 1 , comprising glucoraphanin, myrosinase, ascorbic acid, and a magnesium salt. 
     
     
         7 . The orally administrable composition of  claim 1 , wherein the composition comprises a broccoli extract or powder comprising the sulforaphane precursor. 
     
     
         8 . The orally administrable composition of  claim 1 , wherein the composition comprises an enteric-coated dosage form. 
     
     
         9 . A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and reducing secondary recurrences of a cardiovascular condition or disorder, comprising administering to a subject in need thereof the orally administrable composition of  claim 1 . 
     
     
         10 . The method of  claim 8 , comprising administration of glucoraphanin, myrosinase, ascorbic acid, and a magnesium salt. 
     
     
         11 . An orally administrable composition comprising:
 a broccoli seed extract or powder standardized to contain from about 500 μg to about 2000 mg of a sulforaphane precursor;   a broccoli sprout extract or powder comprising a glucosidase enzyme capable of converting the sulforaphane precursor to sulforaphane;   a cofactor of the enzyme; and   magnesium or a salt or complex thereof;   the orally administrable composition providing a magnesium:sulforaphane precursor ratio of from about 1:1 to about 25:1.   
     
     
         12 . The orally administrable composition of  claim 11 , wherein the sulforaphane precursor comprises glucoraphanin. 
     
     
         13 . The orally administrable composition of  claim 11 , wherein the enzyme capable of converting the sulforaphane precursor to sulforaphane is myrosinase. 
     
     
         14 . The orally administrable composition of  claim 11 , wherein the enzyme cofactor is ascorbic acid. 
     
     
         15 . The orally administrable composition of  claim 11 , wherein the composition comprises an enteric-coated dosage form. 
     
     
         16 . The orally administrable composition of  claim 11 , wherein the composition further comprises one or more additional components selected from the group consisting of:
 vitamin K2, quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiables, a vitamin, coffee fruit, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols.   
     
     
         17 . The orally administrable composition of  claim 11 , comprising glucoraphanin, myrosinase, ascorbic acid, and a magnesium salt. 
     
     
         18 . An orally administrable composition comprising:
 sulforaphane; and   magnesium or a salt or complex thereof;   the orally administrable composition providing a magnesium:sulforaphane ratio of from about 1:1 to about 50:1.   
     
     
         19 . The orally administrable composition of  claim 18 , comprising the sulforaphane in an amount of from about 74 μg to about 750 mg. 
     
     
         20 . The orally administrable composition of  claim 18 , wherein the composition further comprises one or more additional components selected from the group consisting of: vitamin K2, quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiables unsaponifiable, a vitamin, coffee fruit, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols. 
     
     
         21 . The orally administrable composition of  claim 18 , comprising sulforaphane and a magnesium salt. 
     
     
         22 . The orally administrable composition of  claim 18 , wherein the composition comprises an enteric-coated dosage form. 
     
     
         23 . The orally administrable composition of  claim 18 , wherein the composition comprises a broccoli extract or powder comprising sulforaphane. 
     
     
         24 . A method of decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject, comprising administering to the subject in need thereof the orally administrable composition of  claim 18 . 
     
     
         25 . A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject in need thereof, comprising administering to the subject in need thereof the orally administrable composition of  claim 18 .